基因变异改变mRNA表达而不影响蛋白质水平或TAU在阿尔茨海默病中传播
Kunie Ando1, Lidia Lopez-Gutierrez1, Salwa Mansour2
1Alzheimer and Other Tauopathies Research Group, ULB Center for Diabetes Research, Medical Faculty, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), 808 Route de Lennik, B-1070 Brussels, Belgium.
Cells
|February 12, 2026
概括
这就是阿尔茨海默病的原因.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 全基因组关联研究始终将PICALM与阿尔茨海默病 (AD) 风险联系起来.
- 在PICALM中,与AD相关的变异rs3851179的功能影响仍然不清楚.
- 皮卡尔姆是一种克拉特林适应蛋白,对内细胞形成至关重要.
研究的目的:
- 为了研究死后阿尔茨海默病 (AD) 大脑中PICALM mRNA和蛋白质的表达.
- 检查AD相关变异rs3851179和PICALM表达水平之间的关系.
- 在小鼠模型中评估降低PICALM水平对tau病理学的影响.
主要方法:
- 通过rs3851179基因型分层的死后AD大脑中PICALMmRNA和蛋白质水平的分析.
- 测量mRNA与蛋白质的比例,以评估表达效率.
- 使用皮卡尔姆异合性淘汰赛小鼠来建模降低的皮卡尔姆水平,并在注射病理性后评估病理.
主要成果:
- 在AD大脑中,PICALM mRNA水平升高,保护性rs3851179T等位基因与较低的mRNA水平相关.
- 在AD大脑中,PICALM蛋白水平降低.
- 观察到mRNA和蛋白质水平之间的分离,表明非保护性CC基因型载体的蛋白质表达效率降低.
- 在小鼠中降低PICALM水平并没有显著改变tau病理进展.
结论:
- 在阿尔茨海默氏症 (AD) 大脑中,PICALM 蛋白减少,但这种减少似乎没有影响研究小鼠模型中tau 病理的传播.
- 与PICALM变体相关的阿尔茨海默氏病 (AD) 易感性可能涉及超出tau传播的机制,可能与内细胞,血管或自功能有关.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在GWAS中,GWAS就是GWAS.这就是PICALM.国家统一计划 (SNP) 是一个国家统一计划.亚尔吉罗菲尔的谷物是有机的神经纤维状的纠结结合在一起的螺旋丝.子类的传播.qPCRR 是一个很好的方法.知道了,就知道了.更多相关视频
09:12Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes
Published on: December 20, 2019
10:38Using Live-Cell Imaging to Measure the Effects of Pathological Proteins on Axonal Transport in Primary Hippocampal Neurons
Published on: December 22, 2023
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
